nach oben

Erschienen in:

02.05.2018 | SHORT REPORT

Crizotinib-induced simultaneous multiple cardiac toxicities

verfasst von: Takuya Oyakawa, Nao Muraoka, Kei Iida, Masatoshi Kusuhara, Takahisa Kawamura, Tateaki Naito, Toshiaki Takahashi

Erschienen in: Investigational New Drugs | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Summary

Crizotinib is a receptor tyrosine kinase inhibitor that has several targets, including c-ros oncogene 1 and the MET proto-oncogene. Considering its known cardiac toxicity, bradycardia is often investigated following treatment with crizotinib. Our patients had bradycardia, QT prolongation, ventricular rhythm, ventricular fibrillation, and pericarditis simultaneously. The cardiotoxicity of crizotinib can sometimes be simultaneous; thus, intensive observation is needed.

Shaw AT, Ou SH, Bang YJ et al (2014) Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371:1963–1971CrossRefPubMedPubMedCentral

Zamorano JL, Lancellotti P, Rodriguez Muñoz D et al (2016) ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37:2768–2801CrossRefPubMed

Deshpande H, Marler V, Sosa JA (2011) Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer. Onco Targets Ther 4:209–215CrossRefPubMedPubMedCentral

Gallo S, Sala V, Gatti S, Crepaldi T (2015) Cellular and molecular mechanisms of HGF/met in the cardiovascular system. Clin Sci (Lond) 129:1173–1193CrossRef

Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto A, Barlesi F, Akerley W, Orlov S, Santoro A, Spigel D, Hirsh V, Shepherd FA, Sequist LV, Sandler A, Ross JS, Wang Q, von Roemeling R, Shuster D, Schwartz B (2015) Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol 33:2667–2674CrossRefPubMed

Titel: Crizotinib-induced simultaneous multiple cardiac toxicities
verfasst von: Takuya Oyakawa
Nao Muraoka
Kei Iida
Masatoshi Kusuhara
Takahisa Kawamura
Tateaki Naito
Toshiaki Takahashi
Publikationsdatum: 02.05.2018
Verlag: Springer US
Erschienen in: Investigational New Drugs / Ausgabe 5/2018
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-018-0605-x

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Crizotinib-induced simultaneous multiple cardiac toxicities

Summary

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2018

Comparison of published and unpublished phase I clinical cancer trials: an analysis of the CliniclTrials.gov database

SMER28 is a mTOR-independent small molecule enhancer of autophagy that protects mouse bone morrow and liver against radiotherapy

Preclinical investigation of a potent geranylgeranyl diphosphate synthase inhibitor

Oral Metronomic Vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer: outcome and pharmacokinetics in the real world

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer

A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie